Diagnostic Specialty Antibodies Market Research Report by Antibody, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

The Global Diagnostic Specialty Antibodies Market size was estimated at USD 20.85 billion in 2021 and expected to reach USD 21.94 billion in 2022, and is projected to grow at a CAGR 5.38% to reach USD 28.57 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Diagnostic Specialty Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Antibody, the market was studied across Monoclonal Antibodies, Polyclonal Antibodies, and Recombinant Polyclonal Antibodies.

Based on Application, the market was studied across Dengue Diagnostics, HIV Diagnostics, Hepatitis Diagnosis, Infectious Disease Diagnostics, Oncology Diagnostics, and Tuberculosis Diagnostics.

Based on End User, the market was studied across Diagnostic Laboratories and Hospitals.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Diagnostic Specialty Antibodies market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Diagnostic Specialty Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Diagnostic Specialty Antibodies Market, including Abbott Laboratories, Abcam PLC, Abnova, Agilent Technologies, Inc., Aytu BioScience, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioLegend, C.H. Boehringer Sohn AG & Ko. KG, Creative Diagnostics, Enzo Life Sciences, Inc., F. Hoffmann-La Roche AG, HUABIO, Merck KGaA, OriGene Technologies, Inc., Polymun Scientific Immunbiologische Forschung GmbH, R&D Systems by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Synaptic Systems, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Diagnostic Specialty Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diagnostic Specialty Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diagnostic Specialty Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Diagnostic Specialty Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Diagnostic Specialty Antibodies Market?
6. What is the market share of the leading vendors in the Global Diagnostic Specialty Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Diagnostic Specialty Antibodies Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of infectious diseases
5.1.1.2. Rise in government programs concerning diseases treatment
5.1.1.3. Increasing development of healthcare infrastructure
5.1.2. Restraints
5.1.2.1. High cost of monoclonal antibodies
5.1.3. Opportunities
5.1.3.1. Advancement in DNA based technologies and diagnostics
5.1.3.2. High demand for drugs due to COVID-19 pandemic
5.1.4. Challenges
5.1.4.1. Unwanted antibody response with allergic responses
5.2. Cumulative Impact of COVID-19

6. Diagnostic Specialty Antibodies Market, by Antibody
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies
6.4. Recombinant Polyclonal Antibodies

7. Diagnostic Specialty Antibodies Market, by Application
7.1. Introduction
7.2. Dengue Diagnostics
7.3. HIV Diagnostics
7.4. Hepatitis Diagnosis
7.5. Infectious Disease Diagnostics
7.6. Oncology Diagnostics
7.7. Tuberculosis Diagnostics

8. Diagnostic Specialty Antibodies Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratories
8.3. Hospitals

9. Americas Diagnostic Specialty Antibodies Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Diagnostic Specialty Antibodies Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Specialty Antibodies Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abcam PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Abnova
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Agilent Technologies, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Aytu BioScience, Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Becton, Dickinson and Company
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio-Rad Laboratories, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. BioLegend
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. C.H. Boehringer Sohn AG & Ko. KG
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Creative Diagnostics
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Enzo Life Sciences, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. F. Hoffmann-La Roche AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. HUABIO
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck KGaA
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. OriGene Technologies, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Polymun Scientific Immunbiologische Forschung GmbH
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. R&D Systems by Bio-Techne Corporation
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sanofi S.A.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sartorius AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Synaptic Systems
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Thermo Fisher Scientific, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing